Researchers at National Jewish Health found that a subset of children suffering recurring fevers as a result of long COVID-19, benefited from a daily medication treatment commonly used for gout and ...

While conducting the CLEAR SYNERGY (OASIS 9) trial, lead author Sanjit Jolly, MD continued to treat some of his patients post–myocardial infarction (MI), including his late father, with colchicine.

Low-dose colchicine reduces not only MACE but also MI, stroke, and the need for coronary revascularization among patients with known CAD, according to a new meta-analysis that sought to better tease ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — The use of colchicine for gout flare prevention imparts a “modest” decrease in the risk for knee or ...

An anti-inflammatory drug that has been around for over 2,000 years might help delay a very modern problem: hip and knee replacements. That's the suggestion of a new study finding that older adults ...

Colchicine is an oral medication that reduces inflammation and smaller studies have indicated potential benefits for cardiovascular patients. With a placebo-controlled factorial design, CLEAR SYNERGY ...

Please provide your email address to receive an email when new articles are posted on . In patients with chronic coronary disease, the beneficial effects of colchicine were consistent regardless of ...

New Guidelines Issued for Management of Atrial Fibrillation A large-scale study testing the safety of the anti-inflammatory colchicine in treating long-term cardiovascular disease has shown positive ...

BASEL, Switzerland—Low-dose colchicine doesn’t significantly reduce MACE in patients who have had a nonsevere ischemic stroke or high-risk TIA, according to the results of the CONVINCE trial. Through ...

There's new evidence that a 2,000-year-old medicine might offer hope against a modern scourge: COVID-19. The medication, called colchicine, is an anti-inflammatory taken as a pill. It's long been ...

The recent US approval of a new low dose of colchicine 0.5 mg (Lodoco; Agepha Pharma) with a broad indication for use in atherosclerotic cardiovascular disease (ASCVD) represents a completely new ...

I was in my doctor's office last week for new prescriptions, and he indicated that colchicine is being pulled from the market. I take it for gout and don't know what I can use in its place. Do you ...